Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fasiglifam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 known ✓ | O14842 | 20/20 | 1.00 |
| ▸ | GNA15 | P30679 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasiglifam SCHEMBL16448782 | 1.00 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| Fasiglifam SCHEMBL31192643 | 1.00 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| Fasiglifam SCHEMBL29360096 | 1.00 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| Fasiglifam SCHEMBL16448793 | 1.00 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL17471350 | 0.95 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL207981 | 0.95 | FFAR1 (0.90) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL18058590 | 0.94 | FFAR1 (0.88) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL14309260 | 0.92 | FFAR1 (0.85) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL22215870 | 0.92 | FFAR1 (0.85) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL2690226 | 0.92 | FFAR1 (0.85) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | claimed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | claimed |
| US-20130345444-A1 | PRODUCTION METHOD OF OPTICALLY ACTIVE DIHYDROBENZOFURAN DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-26 | — | — | US | claimed |
| EP-2248812-B1 | FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-25 | — | — | EP | claimed |
| US-8598226-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-03 | — | — | US | claimed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | claimed |
| US-8492430-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | claimed |
| EP-2041123-B9 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | claimed |
| EP-2431367-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2012-03-21 | — | — | EP | claimed |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | YASUMA TSUNEO (JP) | 2012-02-23 | — | — | US | claimed |
| EP-2041123-B1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-02-01 | — | — | EP | claimed |
| EP-2248812-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | claimed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | claimed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | claimed |
| US-12364700-B2 | Medical use of pharmaceutical combination or composition | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-22 | — | — | US | disclosed |
| US-12312352-B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| US-20250025470-A1 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-01-23 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
| US-20120046338-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | FFAR1 15/4885GNA15 584/4885SLC10A1 86/4885 |
| US-20250025470-A1 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | DPP4, DPP3, DPP7 | FFAR1 747/4885GNA15 3835/4885SLC10A1 72/4885 |
| US-12312352-B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | DPP4, DPP3, DPP7 | FFAR1 1089/4885GNA15 4436/4885SLC10A1 220/4885 |
| US-20130345444-A1 | PRODUCTION METHOD OF OPTICALLY ACTIVE DIHYDROBENZOFURAN DERIVATIVE | DHPS, DHODH, DHFR | FFAR1 4229/4885GNA15 982/4885SLC10A1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.